605.32 USD
+6.11 (+1.02%)
We assign a fundamental rating of 7 out of 10 to MEDP. MEDP was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making MEDP a very profitable company, without any liquidiy or solvency issues. MEDP is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make MEDP a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
MEDP had positive earnings in the past year.
In the past year MEDP had a positive cash flow from operations.
In the past 5 years MEDP has always been profitable.
In the past 5 years MEDP always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 24.70%, MEDP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
MEDP's Return On Equity of 147.46% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
MEDP's Return On Invested Capital of 91.45% is amongst the best of the industry. MEDP outperforms 100.00% of its industry peers.
MEDP had an Average Return On Invested Capital over the past 3 years of 38.75%. This is significantly above the industry average of 13.75%.
The 3 year average ROIC (38.75%) for MEDP is below the current ROIC(91.45%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
With an excellent Profit Margin value of 18.36%, MEDP belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
In the last couple of years the Profit Margin of MEDP has grown nicely.
MEDP has a better Operating Margin (21.50%) than 89.47% of its industry peers.
In the last couple of years the Operating Margin of MEDP has grown nicely.
MEDP has a worse Gross Margin (31.11%) than 70.18% of its industry peers.
MEDP's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
MEDP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for MEDP has been reduced compared to 1 year ago.
MEDP has less shares outstanding than it did 5 years ago.
MEDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
MEDP has an Altman-Z score of 8.39. This indicates that MEDP is financially healthy and has little risk of bankruptcy at the moment.
MEDP's Altman-Z score of 8.39 is amongst the best of the industry. MEDP outperforms 87.72% of its industry peers.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.39 |
ROIC/WACC8.35
WACC10.95%
2.3 Liquidity
A Current Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.57, MEDP is doing worse than 94.74% of the companies in the same industry.
MEDP has a Quick Ratio of 0.57. This is a bad value and indicates that MEDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MEDP has a Quick ratio of 0.57. This is amonst the worse of the industry: MEDP underperforms 92.98% of its industry peers.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.22%, which is quite impressive.
MEDP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 33.22% yearly.
The Revenue has grown by 13.88% in the past year. This is quite good.
Measured over the past years, MEDP shows a quite strong growth in Revenue. The Revenue has been growing by 19.62% on average per year.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
The Earnings Per Share is expected to grow by 12.31% on average over the next years. This is quite good.
The Revenue is expected to grow by 12.31% on average over the next years. This is quite good.
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 42.33 indicates a quite expensive valuation of MEDP.
Compared to the rest of the industry, the Price/Earnings ratio of MEDP is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 27.25. MEDP is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 36.00, MEDP can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 63.16% of the companies listed in the same industry.
MEDP's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.33 | ||
| Fwd PE | 36 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as MEDP.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MEDP indicates a rather cheap valuation: MEDP is cheaper than 80.70% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.2 | ||
| EV/EBITDA | 30.99 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MEDP does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of MEDP may justify a higher PE ratio.
MEDP's earnings are expected to grow with 13.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.17
PEG (5Y)1.27
EPS Next 2Y15.37%
EPS Next 3Y13.97%
5. Dividend
5.1 Amount
MEDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:MEDP (1/13/2026, 2:51:03 PM)
605.32
+6.11 (+1.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.1%
Inst Owner Change0.55%
Ins Owners0.44%
Ins Owner Change-6.92%
Market Cap17.05B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target550.48 (-9.06%)
Short Float %6.34%
Short Ratio5.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)0.62%
PT rev (3m)27.09%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)11.42%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)5.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)1.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.33 | ||
| Fwd PE | 36 | ||
| P/S | 7.23 | ||
| P/FCF | 25.2 | ||
| P/OCF | 23.97 | ||
| P/B | 58.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.99 |
EPS(TTM)14.3
EY2.36%
EPS(NY)16.81
Fwd EY2.78%
FCF(TTM)24.02
FCFY3.97%
OCF(TTM)25.25
OCFY4.17%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.17
PEG (5Y)1.27
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 8.39 |
F-Score8
WACC10.95%
ROIC/WACC8.35
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.34%
EBIT Next 3Y15.87%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
Can you provide the valuation status for MEDPACE HOLDINGS INC?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
What is the profitability of MEDP stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
What are the PE and PB ratios of MEDPACE HOLDINGS INC (MEDP) stock?
The Price/Earnings (PE) ratio for MEDPACE HOLDINGS INC (MEDP) is 42.33 and the Price/Book (PB) ratio is 58.07.
How financially healthy is MEDPACE HOLDINGS INC?
The financial health rating of MEDPACE HOLDINGS INC (MEDP) is 8 / 10.